Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy

Does the use of glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP) agonists have clinically significant effects on residual gastric volume (RGV) in the periprocedural period?In this randomized clinical trial including 60 US adults with a prespecified interim analysis, the rate of clinically significant RGV was 25.0% vs 3.1% when GLP-1/GIP agonists were continued vs held, respectively, in the periprocedural period. The difference was statistically significant and met the preestablished stopping boundary for study termination.These results suggest that GLP-1 and GIP agonists treatment increases clinically significant RGV during the periprocedural period; however, there was no concomitant increase in aspiration-related adverse events.

Corresponding Author: Tilak Shah, MD, MHS, Department of Gastroenterology, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331 (shaht3@ccf.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.